| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/27/2013 | CN101854914B Stable formulations of amylin and analogues thereof |
| 03/27/2013 | CN101596307B Application of recombinant FN heparin binding domain polypeptide on preparing medicament resisting invasion and metastasis of malignant tumor |
| 03/27/2013 | CN101555279B Urinary follicle stimulating hormone with high purity and preparation method thereof |
| 03/27/2013 | CN101522206B Therapeutic and/or ameliorating agent for disseminated intravascular coagulation |
| 03/27/2013 | CN101519445B Urine follicle-stimulating hormone with high specific activity and method for preparing same |
| 03/27/2013 | CN101389347B Improved antitumoral treatments |
| 03/27/2013 | CN101384622B FGF2-binding peptides and uses thereof |
| 03/27/2013 | CN101381409B N-terminally chemically modified protein compositions and methods |
| 03/27/2013 | CN101381408B Cobratide extraction method, cobratide extracted thereby and formulation containing cobratide |
| 03/27/2013 | CN101374955B Targeting vector-phospholipid conjugates |
| 03/27/2013 | CN101316576B A composition comprising a coupled enzyme system |
| 03/27/2013 | CN101277715B Treatment of neurodegenerative disorders |
| 03/27/2013 | CN101217940B Glp-1类似物制剂 Glp-1 analog formulations |
| 03/27/2013 | CN101188996B Surface-modified microparticles and methods of forming and using the same |
| 03/27/2013 | CN101137390B Novel angiogensis inhibitor |
| 03/27/2013 | CN101052408B Peptides that selectively home to heart vasculature and related conjugates and methods |
| 03/27/2013 | CN101037472B LHRH antagonist with low-histamine releasing function |
| 03/26/2013 | US8404826 Mycobacterial antigens expressed under low oxygen tension |
| 03/26/2013 | US8404814 Anti-EDB antibody-targeted IL-10 cytokine for therapy of rheumatoid arthritis |
| 03/26/2013 | US8404806 Isolated BRCA1 peptides and method of use |
| 03/26/2013 | US8404805 Characterization of GRP94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 03/26/2013 | US8404802 a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma |
| 03/26/2013 | US8404652 Substance which regulates the type-I collagen gene transcription regulating ability |
| 03/26/2013 | US8404648 Polypeptides KXK and their use |
| 03/26/2013 | US8404647 Peptidylarginine deiminase (PAD) inhibitors |
| 03/26/2013 | US8404646 Methods for preventing or treating mitochondrial permeability transition |
| 03/26/2013 | US8404645 Stable formulations of amylin and its analogues |
| 03/26/2013 | US8404644 Agents with angiogenic and wound healing activity |
| 03/26/2013 | US8404643 Metastin derivatives and use thereof |
| 03/26/2013 | US8404642 Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
| 03/26/2013 | US8404640 Method of diagnosing and treating colon cancer |
| 03/26/2013 | US8404639 Methods and kits for treating disease by administering insulin-like growth factor binding protein-2 |
| 03/26/2013 | US8404638 Dimer VEGF antagonist formulations |
| 03/26/2013 | US8404637 GIP analog and hybrid polypeptides with selectable properties |
| 03/26/2013 | US8404636 Targeted delivery of antimicrobial agents |
| 03/26/2013 | US8404635 Orally administered peptides synergize statin activity |
| 03/26/2013 | US8404633 CD5 pharmaceutical compositions for the treatment of infectious and inflammatory processes of fungal origin |
| 03/26/2013 | US8404469 Embedded enzymes in polymers to regulate their degradation rate |
| 03/26/2013 | US8404458 Histone modifications as binary switches controlling gene expression |
| 03/26/2013 | US8404266 Method for stabilization of S-nitrosoglutathione and composition prepared by the same |
| 03/26/2013 | US8404256 Biomaterial composite composition and method of use |
| 03/26/2013 | US8404232 Compositions and methods of using chondroitinase ABCI mutants |
| 03/26/2013 | US8404231 Lysyl oxidase-like 1 (LOXL1) and elastogenesis |
| 03/26/2013 | US8404230 Therapeutic combination comprising a pulmonary surfactant and antioxidant enzymes |
| 03/26/2013 | US8404226 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 03/26/2013 | US8403996 Device for regeneration of articular cartilage and other tissue |
| 03/26/2013 | CA2493957C Method of enhancing biological activity of plant extracts |
| 03/26/2013 | CA2463850C Remodeling of tissues and organs |
| 03/26/2013 | CA2395197C Acyl pseudodipeptides which carry a functionalised auxiliary arm |
| 03/26/2013 | CA2312000C Mammalian cytokine-like polypeptide-10 |
| 03/26/2013 | CA2262459C Gene involved in cadasil, method of diagnosis and therapeutic application |
| 03/21/2013 | WO2013040574A1 Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation |
| 03/21/2013 | WO2013040564A2 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof |
| 03/21/2013 | WO2013040547A2 Compounds and methods of immunization with tumor antigens |
| 03/21/2013 | WO2013040504A2 Srpx for treatment of cancer |
| 03/21/2013 | WO2013040501A1 Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| 03/21/2013 | WO2013040391A2 Novel surface markers for adipose tissues |
| 03/21/2013 | WO2013040341A2 Wnt7a compositions and methods of using the same |
| 03/21/2013 | WO2013040309A2 Wnt compositions and therapeutic uses of such compositions |
| 03/21/2013 | WO2013040141A1 Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| 03/21/2013 | WO2013040093A2 Glucagon-like peptide-2 compositions and methods of making and using same |
| 03/21/2013 | WO2013040080A1 Composition and dressing for wound treatment |
| 03/21/2013 | WO2013040040A1 Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein |
| 03/21/2013 | WO2013039859A1 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| 03/21/2013 | WO2013039597A2 Method for enhancing the growth and fullness of hair |
| 03/21/2013 | WO2013039295A1 Novel alpha 1-antitrypsin variant, preparation method thereof, and use thereof |
| 03/21/2013 | WO2013039244A1 Agent for promoting skeletal muscle regeneration |
| 03/21/2013 | WO2013039056A1 Composition containing soy protein hydrolyzate |
| 03/21/2013 | WO2013038392A1 Peptides useful for binding to b-cell leukemic cells, conjugates, and compositions comprising same and uses thereof |
| 03/21/2013 | WO2013038201A1 Short designed peptides possessing selective actions against bacteria and cancer cells |
| 03/21/2013 | WO2013038137A1 Method of coating microneedle devices |
| 03/21/2013 | WO2013038122A1 Method of coating microneedle devices |
| 03/21/2013 | WO2013037824A1 Endoglycosidase from streptococcus pyogenes and methods using it |
| 03/21/2013 | WO2013037690A1 Glp-1 derivatives |
| 03/21/2013 | WO2013037521A1 Modified hgf-1k1 polypeptide |
| 03/21/2013 | WO2013037520A1 Modified hgf-1k1 polypeptide |
| 03/21/2013 | WO2013037504A1 Systems and methods for diminishing cell growth and inducing selective killing of target cells |
| 03/21/2013 | WO2013037267A1 Variant of liraglutide and conjugate thereof |
| 03/21/2013 | WO2013037090A1 Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof |
| 03/21/2013 | WO2013037066A1 Ocab-based tools for screening of therapeutic agents, treating and diagnosing heart disease associated with cardiac remodeling |
| 03/21/2013 | WO2013036998A1 Treatment of bone diseases |
| 03/21/2013 | WO2013022262A9 Human resistin receptor, and use thereof |
| 03/21/2013 | WO2013016148A3 Natriuretic peptide compositions and methods of preparation |
| 03/21/2013 | WO2013015611A3 Composition for preventing damage to chondrocytes and regenerating same, including yeast hydrolysate as an active ingredient |
| 03/21/2013 | WO2013012954A3 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| 03/21/2013 | WO2013005042A3 Anti-viral therapy |
| 03/21/2013 | WO2012173846A3 Peptidomimetic macrocycles |
| 03/21/2013 | WO2012167028A9 Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition |
| 03/21/2013 | WO2012166859A3 Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| 03/21/2013 | WO2012162555A3 Heparin nanoclusters |
| 03/21/2013 | WO2012161545A3 Composition for promoting apoptosis or inhibiting cell growth, comprising epstein-barr virus microrna |
| 03/21/2013 | WO2012134967A3 Three-dimensional structure of hin1 nucleoprotein in complex with antiviral compounds |
| 03/21/2013 | WO2012127501A3 Composition for improving endometrial thickness during ovarian stimulation |
| 03/21/2013 | US20130072854 Microbubble complexes and methods of use |
| 03/21/2013 | US20130072684 Treatment of t-cell mediated diseases |
| 03/21/2013 | US20130072671 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 03/21/2013 | US20130072667 Use of rgm and its modulators |
| 03/21/2013 | US20130072658 Process for solubilizing glucagon-like peptide 1 compounds |
| 03/21/2013 | US20130072574 Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity |
| 03/21/2013 | US20130072547 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment of prevention of toll-like receptor-4-associated disorders |